Colorectal Cancer

In this first episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, provides a brief overview of Lynch syndrome and its prevalence in the United States and beyond.

Yonina R. Murciano-Goroff, MD, MSc, DPhil, discusses the investigation of the novel KRAS G12C inhibitor LY3537982 in patients with non–small cell lung cancer, colorectal cancer, and other solid tumors.

Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.

Jayesh Desai, MBBS, FRACP, shares data from a phase IB study investigating KRAS G12C inhibitor GDC-6036, or divarasib, in combination with cetuximab for the treatment of patients with colorectal cancer.

Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.

John L. Hays, MD, PhD, discusses the importance of tailoring therapies for patients with CRC who express HER2 or have other actionable targets, the need to develop optimal sequences for local and systemic therapy in CRC, and key updates in hepatocellular carcinoma and pancreatic cancer.

A focused discussion on HER2-amplified colorectal cancer and respective clinical trials that inform use of targeted agents in this setting.

Broadening their conversation, expert oncologists define the treatment algorithm for patients diagnosed with colorectal cancer.

The FDA has granted a fast track designation to the combination of botensilimab plus balstilimab for the treatment of patients with non–microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer with no active liver involvement.

A new genetic test that may allow patients with colorectal cancer to avoid chemotherapy after tumor resection is under investigation at AdventHealth Cancer Institute in Orlando, Florida.

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer.

The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.

Patients with African ancestry with colorectal cancer have fewer actionable gene mutations than those with European ancestry, leading to fewer targeted treatment options in this population.

Alaa Muslimani, MD, discusses the significance of the phase 2 DESTINY-CRC01 and MOUNTAINEER-03 trials on HER2-positive metastatic colorectal cancer treatment in the second line, efforts to expand the use of these agents in earlier disease settings, and the need for more robust clinical data and larger investigations for this population.

In the context of colorectal cancer clinical trials, panelists reflect on the role of liquid biopsies to help inform treatment decisionmaking.

A brief review of HER2 amplification and how it may impact the treatment pathway for patients with a diagnosis of colorectal cancer.

With an overall 5-year survival rate of under 15% in patients with metastatic colorectal cancer, investigators have sought to parse mutational analyses to increase gains.

Micheal Foote, MD, discusses the use of tucatinib plus trastuzumab compared with chemotherapy in the management of HER2-amplified metastatic colorectal cancer.

Daniel Walden, MD, discusses the goal of analyzing RNA expression of wild-type HR genes in CRC, the importance of evaluating the benefit of chemotherapeutic approaches in patients with HRP CRC based on RNA expression levels, and the next steps for validating and implementing these findings in clinical practice.

The phase 3 LEAP-003 and LEAP-017 trials evaluating pembrolizumab plus lenvatinib did not meet their primary end points of overall survival in select patients with unresectable or metastatic melanoma and metastatic colorectal cancer, respectively.

In an era of genomics, proteomics, and immunology a biomarker as simple as anatomy may be useful in terms of predicting responses in patients with colorectal cancer.

Shared insight on appropriate molecular lab testing options that should be explored following a diagnosis of colorectal cancer.

Opening their discussion on colorectal cancer, expert panelists consider its growing prevalence and highlight key molecular subtypes.

John L. Hays, MD, PhD, discusses advances in treating patients with HER2-positive colorectal cancer.

Stacey A. Cohen, MD, discusses the advantages and limitations of ctDNA as a biomarker for detecting minimal residual disease , real-world data on the relationship between fluctuating cfDNA levels and ctDNA detection, and how implementing ctDNA testing earlier to identify minimal residual disease could serve as a prognostic tool in clinical practice.